AEHR heads into its July 8 earnings report having lost nearly a third of its value in a single week — a collapse that makes the print one of the most consequential in the company's recent history.
The stock fell 7.4% on July 7 alone, extending a brutal 30% weekly decline to close at $66.94. That move dwarfs its closest peers: ACLS dropped 19% on the week, while FORM fell 9% and CAMT slid 8%. Even among a weak semiconductor equipment cohort, AEHR's drawdown stands out. Short interest, at 13.8% of free float — roughly 4.1 million shares — has held roughly flat across the past month, ticking up less than 1% on the week. The borrow market tells a similar story of calm: availability is effectively wide open at 974%, meaning there is nearly ten times as much stock available to lend as is currently borrowed. Borrowing costs have actually eased, running near 0.38%. The lending data suggests the sell-off has been driven by holders exiting, not by a fresh wave of short sellers pressing their bets.
Options positioning has shifted sharply toward calls as the stock has collapsed. The put/call ratio dropped to 0.86 — nearly 1.75 standard deviations below its 20-day average of 0.92. That is the most call-heavy reading in months, and one of the most bullish postures in the past year relative to trend. Taken alongside the price collapse, it points to a split market: some participants are treating the drop as a buying opportunity and reaching for upside exposure into the report.
The bull and bear cases were already sharpening before this week's carnage. The most recent analyst moves are dated — the last significant action was William Blair's upgrade to Outperform in early March, when the stock was trading at a fraction of current levels. The mean price target of $71 sits roughly in line with the current price, though most of those estimates predate the recent plunge and should be treated with caution given the scale of the move. Bulls have leaned on Aehr's positioning in wafer-level burn-in for AI and silicon carbide chips, a niche with long replacement cycles and limited competition. Bears point to earnings quality concerns flagged by ORTEX's factor scores — a Piotroski F-Score of just 1, negative ROA, and an EPS momentum rank that has fallen to the 1st percentile over the trailing 90 days. The PE multiple at over 500x leaves almost no room for disappointment. One detail worth noting: the entire C-suite — CEO, CFO, COO, CTO, and several EVPs — all sold shares on July 1-2, just days before the print, though individual transaction sizes were modest.
The earnings report will test whether the revenue and order pipeline can justify a valuation that the factor data increasingly struggles to defend — and whether the week's 30% drawdown already prices in the bad news.
See the live data behind this article on ORTEX.
Open AEHR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
